Juying Zhang

Juying Zhang

Auto-generated profile, based on publicly available information

Juying Zhang

Department of Ultrasound, Affiliated Hospital of North Sichuan Medical College, Innovation Centre for Science and Technology of North Sichuan Medical College, Nanchong, Sichuan, 637000, People’s Republic of China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JZJuying Zhang
Juying Zhang
XLXia Luo
Xia Luo
XYXin Yang
Xin Yang
HLHanmei Li
Hanmei Li
QJQiong Jiang
Qiong Jiang
JYJinhong Yu
Jinhong Yu
Purpose: The incidence of hepatocellular carcinoma (HCC) is continuously increasing, and the mortality rate remains high. Thus, more effective strategies are needed to improve the treatment of HCC. Methods: In this study, we report the use of a visualized glypican-3 (GPC3)-targeting nanodelivery system (named GC-NBs) in combination with sonodynamic therapy (SDT) to enhance the therapeutic efficacy for treating HCC. The obtained nanodelivery system could actively target hepatocellular carcinoma cells and achieve ultrasound imaging through phase changes into nanobubbles under low-intensity ultrasound irradiation. Meanwhile, the released chlorine e6 (Ce6) after the nanobubbles collapse could lead to the generation of reactive oxygen species (ROS) under ultrasound irradiation to induce SDT. Results: Both in vitro and in vivo experiments have shown that GC-NBs can accumulate in tumour areas and achieve sonodynamic antitumour therapy under the navigation action of glypican-3-antibody (GPC3-Ab). Furthermore, in vitro and in vivo experiments did not show significant biological toxicity of the nanodelivery system. Moreover, GC-NBs can be imaged with ultrasound, providing personalized treatment monitoring. Conclusion: GC-NBs enable a visualized antitumour strategy from a targeted sonodynamic perspective by combining tumour-specific targeting and stimuli-responsive controlled release into a single system.

6 January 2025 in Regenerative Biomaterials
Verified
Journal Article
Open access
JZJuying Zhang
Juying Zhang
HLHanmei Li
Hanmei Li
LYLitao Ye
Litao Ye
YLYihan Leng
Yihan Leng
XWXiaoqing Wang
Xiaoqing Wang
JYJinhong Yu
Jinhong Yu
One of the novel forms of programmed cell death, ferroptosis, has recently emerged as a hopeful treatment strategy for triple-negative breast cancer (TNBC). However, insufficient levels of intracellular reactive oxygen species (ROS) and high levels of ROS scavengers in the tumor microenvironment (TME), such as glutathione (GSH), hamper the efficacy of ferroptosis therapy. In this study, the introduction of manganese dioxide nanoparticles (MnO2 NPs) generated cytotoxic hydroxyl radicals (⋅OH) in the TME. Importantly, MnO2 NPs act as a nanosensitizer by consuming H2O2/GSH in the TME, generating oxygen (O2) to relieve the oxygen deficiency of tumors, induce tumor oxidative stress and ultimately enhance SDT-induced ferroptosis. Additionally, oxygen, as an ultrasound contrast agent, enables the visualization of the TNBC treatment process. Meanwhile, GSH depletion in the TME leads to failure of the major cellular system defending against ferroptosis, which also promotes the accumulation of lipid peroxidation in tumor tissue. Specifically, robust autophagy induced by ROS enhances the intracellular iron pool by breaking down ferritin, thereby promoting ferroptosis in cancer cells, leading to the optimal antitumor effect. Consequently, a ferroptosis boosting system that simultaneously encapsulates MnO2 NPs and chlorin e6 (Ce6) was constructed for the intervention of TNBC. Both the in vitro and in vivo results demonstrated that Ce6-MnO2-BSA nanoparticles can generate a significant ROS storm under ultrasound irradiation, eliminating GSH and inducing an autophagic response that increases the effectiveness of ferroptosis, thus, inhibiting the growth of TNBC without obvious toxic side effects. This effective strategy can cascade-augment cancer cell ferroptosis, providing a new perspective for the clinical treatment of TNBC.

1 July 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
HLHan-Mei Li
Han-Mei Li
JZJu-Ying Zhang
Ju-Ying Zhang
XWXiao-Qing Wang
Xiao-Qing Wang
LYLi-Tao Ye
Li-Tao Ye
BRBo Ren
Bo Ren
JYJinhong Yu
Jinhong Yu
Objective: Liver fibrosis replaces healthy tissue with scar tissue, potentially leading to cirrhosis and cancer. ROS drive this process by activating hepatic stellate cells. This study tests the hepatoprotective effects of PDA@CeO2 nanoparticles in scavenging ROS, inhibiting HSC activation, and delaying fibrosis, using 2D-SWE to assess treatment efficacy. Methods: In vitro, flow cytometry evaluated ROS levels in HSCs, scratch assays assessed migration, and α-SMA expression confirmed activation. In vivo, PDA@CeO2 NPs were tested in rats with CCl4-induced liver fibrosis, with effects monitored by 2D-SWE. Histopathological staining and fibrosis markers (Collagen I, α-SMA, TGF-β/Smad3, NOX4) assessed fibrosis progression. Results: In vitro, PDA@CeO2 reduced ROS levels and inhibited HSC migration, with decreased α-SMA expression indicating suppressed activation. In vivo, PDA@CeO2 treatment in CCl4-induced liver fibrosis rats reduced fibrosis markers. 2D-SWE showed improved liver stiffness, and histopathological analysis revealed reduced fibrosis and inflammation. The therapeutic effects were linked to modulation of the NOX4-TGF-β/Smad3 pathway, attenuating fibrosis progression. Conclusion: This study demonstrates the potential of PDA@CeO2 NPs as a novel treatment for liver fibrosis. These nanoparticles scavenge ROS and modulate inflammatory pathways, targeting key signaling mechanisms like the NOX4-TGF-β/Smad3 pathway. PDA@CeO2 NPs offer a promising strategy for attenuating fibrosis at cellular and molecular levels. Additionally, 2D-SWE provides a non-invasive tool for monitoring therapeutic outcomes, positioning PDA@CeO2 NPs as a promising candidate for future clinical liver fibrosis treatments.

22 January 2026 in Regenerative Biomaterials
Verified
Journal Article
Open access
XTXueyao Tang
Xueyao Tang
JZJuying Zhang
Juying Zhang
JZJixuan Zhang
Jixuan Zhang
LHLei Huang
Lei Huang
CLChangbao Li
Changbao Li
YLYing Liu
Ying Liu
Activated hepatic stellate cells (HSCs) are the primary drivers of pathological extracellular matrix accumulation in liver fibrosis. Thus, inhibiting HSC activation is crucial for treatment; however, therapeutic efficacy often falls short of expectations. A major obstacle is the hypoxic, reactive oxygen species (ROS)-rich microenvironment, which fuels persistent HSC activation and compromises long-term treatment success. Here, we developed an activated HSC-targeted biomimetic nanozyme, HSC-HMMDN, by coating hollow mesoporous manganese dioxide nanoparticles (HMMDN) with membranes derived from activated HSCs to synergistically clear ROS and alleviate hypoxia. This homologous coating strategy enables precise recognition of surface adhesion molecules (such as integrins and N-cadherin) that are highly expressed on activated HSCs, ensuring targeted delivery. Once there, the nanozyme, endowed with superoxide dismutase- and catalase-like activities, scavenges excessive ROS, revives mitochondrial function and suppresses the TGF-β/Smad cascade to inhibit HSC activation. In a carbon tetrachloride (CCl4)-induced liver fibrosis rat model, HSC-HMMDN significantly ameliorated fibrosis and alleviated the hypoxic microenvironment without showing detectable toxicity. Overall, this targeted microenvironment remodeling strategy provides a new avenue for liver fibrosis therapy.